

Scarelon REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION REQUEST FORM

Please Fax to Carelon at 1.800.370.1116

☐ In Network			☐ Out of Network			
Member Name:			DOB:	Gender:		
Health Plan:				Policy:		
Provider Name:				Provider ID:		
Address:			Email:			
Direct Phone:			Fax:			
NPI:			Tax ID:			
Primary Contact:						
1. Has a confirm	ned diagnosis of severe	major depressive di	sorder (MDD) single or recu	rrent episode:		
□ F32.2	Major Depressive Disorder, Single Episode, Severe (Without Psychotic Features)					
□ F33.2	Major Depressive Disorder, Recurrent Episode, Severe (Without Psychotic Features)					
2. Does the Me	mber have one or mor	e of the following?				
psychopharm must have be Inability to tole agent classes	acologic agents in the cur en administered at an ad- erate psychopharmacolog s with distinct side effects	rent depressive episod equate course of mono ic agents as evidenced	le from at least two different ag - or poly-drug therapy) I by two trials of psychopharm	ly significant response to one trial of gent classes. (Each agent in the treatment trial acological agents from at least two different		
☐ Currently rece option	eiving or is a candidate fo	r and has declined elec	troconvulsive therapy (ECT) a	nd TMS is considered a less invasive treatment		
3. Does the Me	mber have a history of	TMS attempts in the	e past?			
☐ Yes ☐ No Dates:						
4. Has the Men	nber had an adequate t	rial of evidence-base	d psychotherapy, without s	significant improvement within the past 5 years?		
Dates of evidence	e-based psychotherapy t	rial:	sychotherapy, what is the reas			
5. Please fill in	the Member's psychotr	opic medications tal	cen within the past five year	's:		
Medicatio	on Name	Dose	Response (Start and End Date)	Response (Atypical Agents)		
			,	☐ Improved ☐ Inadequate Response ☐ Adverse Response ☐ Intolerability ☐ Non-Adherence ☐ Other:		
				 ☐ Improved ☐ Inadequate Response ☐ Adverse Response ☐ Intolerability ☐ Non-Adherence ☐ Other: 		
				☐ Improved ☐ Inadequate Response ☐ Adverse Response ☐ Intolerability ☐ Non-Adherence ☐ Other:		

Medication Name	Dose	Response (Start an	d Response (Atypical Agents)					
		End Date)						
			☐ Improved ☐ Inadequate Response					
			☐ Adverse Response ☐ Intolerability ☐ Non-Adherence ☐ Other:					
			☐ Improved ☐ Inadequate Response					
			☐ Adverse Response ☐ Intolerability					
			☐ Non-Adherence ☐ Other:					
			☐ Improved ☐ Inadequate Response					
			☐ Adverse Response ☐ Intolerability					
			☐ Non-Adherence ☐ Other:					
Please list any Augmenting Agents used: _ If no medications were used, are they cont \(\subseteq \text{Yes} \) \(\subseteq \text{No} \)								
6. Were any of these meds used durin	g this depressive	e episode?						
☐ Yes, list medications:		-						
□ No								
If yes, was improvement inadequate at adequate dose and duration?								
☐ Yes, list dose and duration:								
□ No								
I	If yes, was the medication discontinued due to side effects?							
☐ Yes, list side effects:								
7. Please check all that apply:								
☐ Vagus Nerve Stimulator leads in the ca	rotid sheath							
☐ Other implanted stimulators controlled by or that use electrical or magnetic signals								
_	-	netals implanted or embed	lded in head or neck within 11.81 inches (30 cm) of TMS					
coil placement other than dental fillings								
☐ Acute or chronic psychotic symptoms or disorder								
□ Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of								
repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system Seizure disorder or history of seizures								
La seizure disorder of filstory of seizures								
□ Substance abuse at time of treatments								
□ Pregnant or nursing								
☐ Current suicide plan or suicide attempt								
□ Non-adherence with previous depression treatments								
History of: ☐ Bipolar Disorder ☐ PTSD ☐ OCD ☐ Eating Disorder								
□ None of the above								
	score on a valida	nted self-report depressi	on scale (PHQ-9, MADRS, BDI, HAM-D, GDS, etc.)					
Rating scale used:		Score:						
Date completed:								
9. Treatment Request								
Code		Units	Start Date End Date					
90867: initial, including cortical mapping, r								
threshold determination, and delivery man	agement							
00060 subsequent delivery and response	-nt							
90868: subsequent delivery and managem per session	EIIL							
PCI 3C331011								
90869: subsequent motor threshold redete	ermination							
with delivery and management								
,								